DMRA
Price
$21.75
Change
+$0.22 (+1.02%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.33B
14 days until earnings call
Intraday BUY SELL Signals
RANI
Price
$0.59
Change
-$0.02 (-3.28%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
69.83M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMRA vs RANI

DMRA vs RANI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMRA vs. RANI commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMRA is a Buy and RANI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DMRA with price predictions
Oct 21, 2026

DMRA's RSI Oscillator recovers from oversold territory

The RSI Indicator for DMRA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 27 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 65 cases where DMRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMRA as a result. In 77 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for DMRA just turned positive on October 07, 2026. Looking at past instances where DMRA's MACD turned positive, the stock continued to rise in 43 of 47 cases over the following month. The odds of a continued upward trend are 90%.

Following a +11.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMRA advanced for three days, in 205 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

DMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for DMRA moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for DMRA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.443) is normal, around the industry mean (2.988). DMRA has a moderately low P/E Ratio (-82.808) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. DMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for RANI with price predictions
Oct 21, 2026

RANI's RSI Indicator slumps into oversold zone

The RSI Indicator for RANI moved into overbought territory on October 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where RANI advanced for three days, in 203 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

RANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RANI as a result. In 103 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for RANI turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

RANI moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RANI crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RANI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for RANI entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.780) is normal, around the industry mean (2.988). P/E Ratio (-4.654) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (21.459) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
DMRA: Fundamental Ratings
DMRA
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
PROFIT vs RISK RATING
1..100
43
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
39

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DMRARANI
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (DMRA: $21.53 vs. RANI: $0.61)
Brand notoriety: DMRA and RANI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMRA: 105% vs. RANI: 108%
Market capitalization -- DMRA: $1.34B vs. RANI: $67.82M
DMRA [@Biotechnology] is valued at $1.34B. RANI’s [@Biotechnology] market capitalization is $67.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMRA’s FA Score shows that 2 FA rating(s) are green while RANI’s FA Score has 2 green FA rating(s).

  • DMRA’s FA Score: 2 green, 3 red.
  • RANI’s FA Score: 2 green, 3 red.
According to our system of comparison, DMRA is a better buy in the long-term than RANI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMRA’s TA Score shows that 6 TA indicator(s) are bullish while RANI’s TA Score has 4 bullish TA indicator(s).

  • DMRA’s TA Score: 6 bullish, 3 bearish.
  • RANI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DMRA is a better buy in the short-term than RANI.

Price Growth

DMRA (@Biotechnology) experienced а +16.82% price change this week, while RANI (@Biotechnology) price change was -9.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

DMRA is expected to report earnings on Nov 05, 2026.

RANI is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMRA
Daily Signal:
Gain/Loss:
RANI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

DMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMRA has been closely correlated with COGT. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if DMRA jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMRA
1D Price
Change %
DMRA100%
+4.16%
COGT - DMRA
74%
Closely correlated
+0.61%
NERV - DMRA
45%
Loosely correlated
-5.53%
INBX - DMRA
44%
Loosely correlated
+3.03%
RANI - DMRA
44%
Loosely correlated
-7.32%
GNTA - DMRA
38%
Loosely correlated
+4.92%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ACLC86.780.62
+0.72%
American Century Large Cap Equity ETF (ACLC)
YYYM17.21N/A
N/A
Amplify Municipal CEF High Income ETF (YYYM)
KBE64.30-0.06
-0.09%
State Street SPDR S&P Bank ETF (KBE)
RMI13.67-0.08
-0.58%
RiverNorth Opportunistic Municipal Income Fund
NFLU12.63-1.53
-10.81%
T-Rex 2X Long NFLX Daily Target ETF (NFLU)